Inhibitor Therapeutics (INTI) Total Non-Current Liabilities (2012)
Inhibitor Therapeutics' Total Non-Current Liabilities came in at $559,953 for Q4 2012.
Powered by 
Analysis
Inhibitor Therapeutics (INTI) Total Non-Current Liabilities (2012) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 80.25 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -967.00 Mn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 81.11 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 36.04 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 5.92 Bn |
| 10 | Inhibitor Therapeutics | 17.38 Mn | 17.38 Mn | - | - |
API Access
Inhibitor Therapeutics Total Non-Current Liabilities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=INTI&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "total-non-current-liabilities", "ticker": "INTI", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=INTI&period=max&api_key=YOUR_API_KEY");
const data = await res.json();